PMCB vs TROW · $8.6M cap vs P/E 12, rev $7.09B
PharmaCyte Biotech Inc (PMCB) versus T. Rowe Price Group Inc (TROW) — a side-by-side from cached financials, not a winner call.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
T. Rowe Price Group Inc (TROW) is a asset management company listed on NASDAQ.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
Latest reported TROW revenue for 2024-12-31 was $7.09B. Net income was $2.14B. Revenue was up 9.8% from 2023-12-31 to 2024-12-31. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
PMCB currently screens at market cap $8.6M. TROW currently screens at market cap $23.17B and trailing P/E 11.6.
Not investment advice. Open the PMCB and TROW stock pages for the full models.
Not investment advice.